Clinical Trials Directory

Trials / Completed

CompletedNCT02145260

Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

Randomized Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
144 (actual)
Sponsor
Brigham and Women's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Intra-dialytic hypotensive (IDH) events can be defined as an abrupt decline in blood pressure that cause symptoms and/or require an intervention. They are common, affecting up to one third of maintenance HD sessions. Detrimental associations include: development of myocardial stunning, cerebral hypo-perfusion, vascular access thrombosis and greater mortality. Rapid solute removal by HD generates temporary osmotic gradients between the intra-vascular and intra-cellular compartments, promoting trans-cellular fluid movement and resultant hypotension. Manipulation of osmotic gradients, e.g. using higher dialysate sodium (DNa), may ameliorate excess SBP decline during HD. This study aims to assess the effects of higher (142 mmol/L) versus lower (138 mmol/L) dialysate sodium (DNa) use in adult chronic hemodialysis patients admitted to hospital on intra-dialytic blood pressure and biomarkers of cardiac ischemia. The investigators will randomly assign subjects to higher versus lower DNa during their hospital stay, up to a maximum of six HD sessions.

Conditions

Interventions

TypeNameDescription
DRUGLower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
DRUGHigher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)A higher dialysate sodium will be used in the experimental arm (142 mmol/L)

Timeline

Start date
2014-07-01
Primary completion
2020-12-31
Completion
2021-05-03
First posted
2014-05-22
Last updated
2022-10-31
Results posted
2022-10-31

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02145260. Inclusion in this directory is not an endorsement.